REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

384 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-30

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Daprodustat Hepatic Impairment Study

NCT03223337

Anaemia

COMPLETED PHASE1

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

NCT05515367

Chronic Kidney Diseases Anemia of Chronic Kidney Disease

RECRUITING PHASE4

Evaluation of Renastep

NCT03602937

Chronic Kidney Diseases Renal Disease

COMPLETED NA

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

NCT01736397

Iron Deficiency Iron Deficiency Anemia

COMPLETED PHASE2

Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients

NCT06903559

Kidney Failure, Chronic Malnutrition-Inflammation Syndrome Anemia in End Stage Renal Disease +1 more

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CKD Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Daprodustat arm for CKD anemia patients

Daprodustat

Intervention Type DRUG

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Daprodustat

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)

* Patients on hemodialysis (HD) or peritoneal dialysis (PD)
* Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion Criteria

1. Acute Kidney Injury (AKI) without underlying chronicity
2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
3. Refusal or inability to provide consent
4. Current enrollment in an interventional trial that restricts real-world data collection
5. Life expectancy \< 3 months, where follow-up is not feasible
6. Known contraindications to Daprodustat as per local prescribing information

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No